Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France

The Breast · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles